Inositec AG
Developing small molecules to address unmet medical needs
Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate (IP6) analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. The lead compound INS-3001 is a cardiovascular calcification inhibitor in development for aortic valve stenosis. Inositec was founded in December 2015 based on the award-winning research of Dr. Mattias Ivarsson, Prof. Jean-Christophe Leroux and Prof. Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at www.inositec.com.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
22.11.2021
Vifor Pharma to acquire Inositec (startupticker.ch)
22.11.2021
Inositec gets acquired by Vifor Pharma to advance the vascular calcification field (venturelab.swiss)
06.02.2020
Successful proof-of-concept for Inositec's lead candidate (startupticker.ch)
08.01.2019
Seven startups receive the first Innosuisse Certificates (startupticker.ch)
30.10.2018
Inositec to launch clinical studies for its drug against kidney-related issues (startupticker.ch)
Last Tweets
No milestones
No Jobs
No videos and documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Technology
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Inositec AG
Developing small molecules to address unmet medical needs
Website:
www.inositec.com/
Vifor Pharma
Headquarter:
Zurich
Foundation Date:
December 2015
Technology:
- Biotech
Sectors:
- Biotech
- Cardiovascular
- Drug development platforms
- Drug discovery
- Infection
- Small molecule drugs
- Urology
Support received
